Drug intelligence / Profile preview

spirulina-based malaria vaccine

Development stage: Preclinical
Lead developer: Lumen Bioscience
Modality: Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Vaccines & Immunotherapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Recombinant Proteins and Enzymes, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Intranasal, Oral

Overview

This spirulina-based malaria vaccine is an investigational intranasal and oral vaccine developed by Lumen Bioscience for the prevention of malaria. The vaccine utilizes genetically engineered spirulina (Arthrospira platensis), a photosynthetic cyanobacterium, to express virus-like particles (VLPs) that display the NANP repeat region of the Plasmodium falciparum circumsporozoite protein (PfCSP). Administered as an intranasal prime followed by oral booster doses, the vaccine is designed to induce both systemic and mucosal immune responses, targeting the pre-erythrocytic stage of the parasite to prevent liver infection. The platform offers a low-cost, scalable, and shelf-stable alternative to traditional vaccines, potentially eliminating the need for cold-chain logistics and trained medical personnel in endemic regions.

Other names: intranasal malaria vaccine

Targets

CSP (Circumsporozoite protein)

Beyond the preview

Go deeper on spirulina-based malaria vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on spirulina-based malaria vaccine.

Explore the full profile